Executive Interview – TruScreen

Executive Interview – TruScreen

TruScreen (TRU) listed on the NZX in November 2014. The company manufactures and distributes a unique testing device that detects cancerous and pre-cancerous cells in the cervix. The developing world, which has the highest incidence and mortality from cervical cancer, is its target market. TRU has secured China Food and Drug Administration (CFDA) approval to market TruScreen in China and has recently received certification in Mexico. TRU has distribution contracts in 11 international markets, including China, Latin America, Central Asia, Russia, the Middle East and Eastern Europe.

In this interview CEO Martin Dillon discusses the rationale behind TruScreen’s market entry into China, the benefits of the company’s testing device and its future growth strategy, including the launch of new products.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.